Search

Your search keyword '"Calaminus, Gabriele"' showing total 600 results
Start Over Author "Calaminus, Gabriele"
600 results on '"Calaminus, Gabriele"'

154. Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy

Author

Calaminus, Gabriele, primary, Jenney, Meriel, additional, Hjorth, Lars, additional, Baust, Katja, additional, Bernstein, Mark, additional, Bielack, Stefan, additional, Vos, Patricia De, additional, Hogendoorn, Pancras C W, additional, Jovic, Gordana, additional, Krailo, Mark, additional, Kreitz, Kiana, additional, Marina, Neyssa, additional, Popoola, Babasola O, additional, Sauerland, Cristina, additional, Smeland, Sigbjørn, additional, Teske, Carmen, additional, Schweinitz, Clara V, additional, Whelan, Jeremy, additional, Wiener, Andreas, additional, Sydes, Matthew R, additional, and Nagarajan, Rajaram, additional

Published
2019
Full Text
View/download PDF

159. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Author

Smeland, Sigbjørn, primary, Bielack, Stefan S., additional, Whelan, Jeremy, additional, Bernstein, Mark, additional, Hogendoorn, Pancras, additional, Krailo, Mark D., additional, Gorlick, Richard, additional, Janeway, Katherine A., additional, Ingleby, Fiona C., additional, Anninga, Jakob, additional, Antal, Imre, additional, Arndt, Carola, additional, Brown, Ken L.B., additional, Butterfass-Bahloul, Trude, additional, Calaminus, Gabriele, additional, Capra, Michael, additional, Dhooge, Catharina, additional, Eriksson, Mikael, additional, Flanagan, Adrienne M., additional, Friedel, Godehard, additional, Gebhardt, Mark C., additional, Gelderblom, Hans, additional, Goldsby, Robert, additional, Grier, Holcombe E., additional, Grimer, Robert, additional, Hawkins, Douglas S., additional, Hecker-Nolting, Stefanie, additional, Sundby Hall, Kirsten, additional, Isakoff, Michael S., additional, Jovic, Gordana, additional, Kühne, Thomas, additional, Kager, Leo, additional, von Kalle, Thekla, additional, Kabickova, Edita, additional, Lang, Susanna, additional, Lau, Ching C., additional, Leavey, Patrick J., additional, Lessnick, Stephen L., additional, Mascarenhas, Leo, additional, Mayer-Steinacker, Regine, additional, Meyers, Paul A., additional, Nagarajan, Raj, additional, Randall, R.Lor, additional, Reichardt, Peter, additional, Renard, Marleen, additional, Rechnitzer, Catherine, additional, Schwartz, Cindy L., additional, Strauss, Sandra, additional, Teot, Lisa, additional, Timmermann, Beate, additional, Sydes, Matthew R., additional, and Marina, Neyssa, additional

Published
2019
Full Text
View/download PDF

160. Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study

Author

Scholtes, Cathy, primary, Baust, Katja, additional, Weinhold, Leonie, additional, Creutzig, Ursula, additional, Gnekow, Astrid, additional, Hinz, Andreas, additional, Kaatsch, Peter, additional, Kreitz, Kiana, additional, Langer, Thorsten, additional, Rutkowski, Stefan, additional, Singer, Susanne, additional, Spix, Claudia, additional, Teske, Carmen, additional, Schmid, Matthias, additional, Dilloo, Dagmar, additional, and Calaminus, Gabriele, additional

Published
2019
Full Text
View/download PDF

162. PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents

Author

Byrne, Julianne, primary, Grabow, Desiree, additional, Campbell, Helen, additional, O'Brien, Kylie, additional, Bielack, Stefan, additional, am Zehnhoff-Dinnesen, Antoinette, additional, Calaminus, Gabriele, additional, Kremer, Leontien, additional, Langer, Thorsten, additional, van den Heuvel-Eibrink, Marry M., additional, van Dulmen-den Broeder, Eline, additional, Baust, Katja, additional, Bautz, Andrea, additional, Beck, Jörn D., additional, Berger, Claire, additional, Binder, Harald, additional, Borgmann-Staudt, Anja, additional, Broer, Linda, additional, Cario, Holger, additional, Casagranda, Leonie, additional, Clemens, Eva, additional, Deuster, Dirk, additional, de Vries, Andrica, additional, Dirksen, Uta, additional, Winther, Jeanette Falck, additional, Fosså, Sophie, additional, Font-Gonzalez, Anna, additional, Grandage, Victoria, additional, Haupt, Riccardo, additional, Hecker-Nolting, Stefanie, additional, Hjorth, Lars, additional, Kaiser, Melanie, additional, Kenborg, Line, additional, Kepak, Tomas, additional, Kepáková, Kateřina, additional, Knudsen, Lisbeth E., additional, Krawczuk-Rybak, Maryna, additional, Kruseova, Jarmila, additional, Kuehni, Claudia E., additional, Kunstreich, Marina, additional, Kuonen, Rahel, additional, Lackner, Herwig, additional, Leiper, Alison, additional, Loeffen, Erik A.H., additional, Luks, Ales, additional, Modan-Moses, Dalit, additional, Mulder, Renee, additional, Parfitt, Ross, additional, Paul, Norbert W., additional, Ranft, Andreas, additional, Ruud, Ellen, additional, Schilling, Ralph, additional, Spix, Claudia, additional, Stefanowicz, Joanna, additional, Strauβ, Gabriele, additional, Uitterlinden, Andre G., additional, van den Berg, Marleen, additional, van der Kooi, Anne-Lotte, additional, van Dijk, Marloes, additional, van Leeuwen, Flora, additional, Zolk, Oliver, additional, Zöller, Daniela, additional, Kaatsch, Peter, additional, Kaatsch, P., additional, Grabow, D., additional, Byrne, J., additional, Campbell, H., additional, Clissmann, C., additional, O'Brien, K., additional, Kremer, L.C.M., additional, Langer, T., additional, van Dulmen-den Broeder, E., additional, van den Berg, Dr. MH., additional, van den Heuvel-Eibrink, M.M., additional, Borgmann-Staudt, A., additional, am Zehnhoff-Dinnesen, A., additional, Kuehni, C.E., additional, Haupt, R., additional, Kepak, T., additional, Berger, C., additional, Winther, J.F., additional, Kruseova, J., additional, Calaminus, G., additional, Baust, K., additional, Dirksen, U., additional, van Leeuwen, F., additional, Schilling, R., additional, Strauss, G., additional, Ranft, A., additional, Garré, M.-L., additional, Fosså, S., additional, Leiper, A., additional, Lackner, H., additional, Panasiuk, A., additional, Krawczuk-Rybak, Dr. M., additional, Kunstreich, M., additional, Cario, H., additional, Zolk, O., additional, Bielack, S., additional, Stefanowicz, J., additional, Grandage, V., additional, and Modan, D., additional

Published
2018
Full Text
View/download PDF

163. Quality of survival in SIOPE brain tumour clinical trials for children aged less than 5 years: Development of a clinical trial protocol

Author

Endocrinologie patientenzorg, Child Health, Limond, Jenny, Thomas, Sophie, Bull, Kim, Lemiere, Jurgen, Traunwieser, Thomas, Spoudeas, Helen, van Santen, HM, Weiler-Wichtl, Liesa J., Lüttich, Peggy, Calaminus, Gabriele, Chevignard, Mathilde P., Endocrinologie patientenzorg, Child Health, Limond, Jenny, Thomas, Sophie, Bull, Kim, Lemiere, Jurgen, Traunwieser, Thomas, Spoudeas, Helen, van Santen, HM, Weiler-Wichtl, Liesa J., Lüttich, Peggy, Calaminus, Gabriele, and Chevignard, Mathilde P.

Published
2018

164. DNA methylation-based classification of central nervous system tumours

Author

Pathologie Pathologen staf, Capper, David, Jones, David T.W., Sill, Martin, Hovestadt, Volker, Schrimpf, Daniel, Sturm, Dominik, Koelsche, Christian, Sahm, Felix, Chavez, Lukas, Reuss, David E., Kratz, Annekathrin, Wefers, Annika K., Huang, Kristin, Pajtler, Kristian W., Schweizer, Leonille, Stichel, Damian, Olar, Adriana, Engel, Nils W., Lindenberg, Kerstin, Harter, Patrick N., Braczynski, Anne K., Plate, Karl H., Dohmen, Hildegard, Garvalov, Boyan K., Coras, Roland, Hölsken, Annett, Hewer, Ekkehard, Bewerunge-Hudler, Melanie, Schick, Matthias, Fischer, Roger, Beschorner, Rudi, Schittenhelm, Jens, Staszewski, Ori, Wani, Khalida, Varlet, Pascale, Pages, Melanie, Temming, Petra, Lohmann, Dietmar, Selt, Florian, Witt, Hendrik, Milde, Till, Witt, Olaf, Aronica, Eleonora, Giangaspero, Felice, Rushing, Elisabeth, Scheurlen, Wolfram, Geisenberger, Christoph, Rodriguez, Fausto J., Becker, Albert, Preusser, Matthias, Haberler, Christine, Bjerkvig, Rolf, Cryan, Jane, Farrell, Michael, Deckert, Martina, Hench, Jürgen, Frank, Stephan, Serrano, Jonathan, Kannan, Kasthuri, Tsirigos, Aristotelis, Brück, Wolfgang, Hofer, Silvia, Brehmer, Stefanie, Seiz-Rosenhagen, Marcel, Hänggi, Daniel, Hans, Volkmar, Rozsnoki, Stephanie, Hansford, Jordan R., Kohlhof, Patricia, Kristensen, Bjarne W., Lechner, Matt, Lopes, Beatriz, Mawrin, Christian, Ketter, Ralf, Kulozik, Andreas, Khatib, Ziad, Heppner, Frank, Koch, Arend, Jouvet, Anne, Keohane, Catherine, Mühleisen, Helmut, Mueller, Wolf, Pohl, Ute, Prinz, Marco, Benner, Axel, Zapatka, Marc, Gottardo, Nicholas G., Driever, Pablo Hernáiz, Kramm, Christof M., Müller, Hermann L., Rutkowski, Stefan, Von Hoff, Katja, Frühwald, Michael C., Gnekow, Astrid, Fleischhack, Gudrun, Tippelt, Stephan, Calaminus, Gabriele, Monoranu, Camelia Maria, Perry, Arie, Jones, Chris, Jacques, Thomas S., Radlwimmer, Bernhard, Gessi, Marco, Pietsch, Torsten, Schramm, Johannes, Schackert, Gabriele, Westphal, Manfred, Reifenberger, Guido, Wesseling, Pieter, Weller, Michael, Collins, Vincent Peter, Blümcke, Ingmar, Bendszus, Martin, Debus, Jürgen, Huang, Annie, Jabado, Nada, Northcott, Paul A., Paulus, Werner, Gajjar, Amar, Robinson, Giles W., Taylor, Michael D., Jaunmuktane, Zane, Ryzhova, Marina, Platten, Michael, Unterberg, Andreas, Wick, Wolfgang, Karajannis, Matthias A., Mittelbronn, Michel, Acker, Till, Hartmann, Christian, Aldape, Kenneth, Schüller, Ulrich, Buslei, Rolf, Lichter, Peter, Kool, Marcel, Herold-Mende, Christel, Ellison, David W., Hasselblatt, Martin, Snuderl, Matija, Brandner, Sebastian, Korshunov, Andrey, Von Deimling, Andreas, Pfister, Stefan M., Pathologie Pathologen staf, Capper, David, Jones, David T.W., Sill, Martin, Hovestadt, Volker, Schrimpf, Daniel, Sturm, Dominik, Koelsche, Christian, Sahm, Felix, Chavez, Lukas, Reuss, David E., Kratz, Annekathrin, Wefers, Annika K., Huang, Kristin, Pajtler, Kristian W., Schweizer, Leonille, Stichel, Damian, Olar, Adriana, Engel, Nils W., Lindenberg, Kerstin, Harter, Patrick N., Braczynski, Anne K., Plate, Karl H., Dohmen, Hildegard, Garvalov, Boyan K., Coras, Roland, Hölsken, Annett, Hewer, Ekkehard, Bewerunge-Hudler, Melanie, Schick, Matthias, Fischer, Roger, Beschorner, Rudi, Schittenhelm, Jens, Staszewski, Ori, Wani, Khalida, Varlet, Pascale, Pages, Melanie, Temming, Petra, Lohmann, Dietmar, Selt, Florian, Witt, Hendrik, Milde, Till, Witt, Olaf, Aronica, Eleonora, Giangaspero, Felice, Rushing, Elisabeth, Scheurlen, Wolfram, Geisenberger, Christoph, Rodriguez, Fausto J., Becker, Albert, Preusser, Matthias, Haberler, Christine, Bjerkvig, Rolf, Cryan, Jane, Farrell, Michael, Deckert, Martina, Hench, Jürgen, Frank, Stephan, Serrano, Jonathan, Kannan, Kasthuri, Tsirigos, Aristotelis, Brück, Wolfgang, Hofer, Silvia, Brehmer, Stefanie, Seiz-Rosenhagen, Marcel, Hänggi, Daniel, Hans, Volkmar, Rozsnoki, Stephanie, Hansford, Jordan R., Kohlhof, Patricia, Kristensen, Bjarne W., Lechner, Matt, Lopes, Beatriz, Mawrin, Christian, Ketter, Ralf, Kulozik, Andreas, Khatib, Ziad, Heppner, Frank, Koch, Arend, Jouvet, Anne, Keohane, Catherine, Mühleisen, Helmut, Mueller, Wolf, Pohl, Ute, Prinz, Marco, Benner, Axel, Zapatka, Marc, Gottardo, Nicholas G., Driever, Pablo Hernáiz, Kramm, Christof M., Müller, Hermann L., Rutkowski, Stefan, Von Hoff, Katja, Frühwald, Michael C., Gnekow, Astrid, Fleischhack, Gudrun, Tippelt, Stephan, Calaminus, Gabriele, Monoranu, Camelia Maria, Perry, Arie, Jones, Chris, Jacques, Thomas S., Radlwimmer, Bernhard, Gessi, Marco, Pietsch, Torsten, Schramm, Johannes, Schackert, Gabriele, Westphal, Manfred, Reifenberger, Guido, Wesseling, Pieter, Weller, Michael, Collins, Vincent Peter, Blümcke, Ingmar, Bendszus, Martin, Debus, Jürgen, Huang, Annie, Jabado, Nada, Northcott, Paul A., Paulus, Werner, Gajjar, Amar, Robinson, Giles W., Taylor, Michael D., Jaunmuktane, Zane, Ryzhova, Marina, Platten, Michael, Unterberg, Andreas, Wick, Wolfgang, Karajannis, Matthias A., Mittelbronn, Michel, Acker, Till, Hartmann, Christian, Aldape, Kenneth, Schüller, Ulrich, Buslei, Rolf, Lichter, Peter, Kool, Marcel, Herold-Mende, Christel, Ellison, David W., Hasselblatt, Martin, Snuderl, Matija, Brandner, Sebastian, Korshunov, Andrey, Von Deimling, Andreas, and Pfister, Stefan M.

Published
2018

165. PanCareLIFE:The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents

Author

Byrne, Julianne, Grabow, Desiree, Campbell, Helen, O'Brien, Kylie, Bielack, Stefan, Zehnhoff-Dinnesen, Antoinette Am, Calaminus, Gabriele, Kremer, Leontien, Langer, Thorsten, van den Heuvel-Eibrink, Marry M., van Dulmen-den Broeder, Eline, Baust, Katja, Bautz, Andrea, Beck, Jörn D., Berger, Claire, Binder, Harald, Borgmann-Staudt, Anja, Broer, Linda, Cario, Holger, Casagranda, Leonie, Clemens, Eva, Deuster, Dirk, de Vries, Andrica, Dirksen, Uta, Winther, Jeanette Falck, Fossa, Sophie, Font-Gonzalez, Anna, Grandage, Victoria, Haupt, Riccardo, Hecker-Nolting, Stefanie, Hjorth, Lars, Kaiser, Melanie, Kenborg, Line, Kepak, Tomas, Kepakova, Katerina, Knudsen, Lisbeth E., Krawczuk-Rybak, Maryna, Kruseova, Jarmila, Kuehni, Claudia E., Kunstreich, Marina, Kuonen, Rahel, Lackner, Herwig, Leiper, Alison, Loeffen, Erik A. H., Luks, Ales, Modan-Moses, Dalit, Mulder, Renee, Parfitt, Ross, Paul, Norbert W., Ranft, Andreas, Ruud, Ellen, Schilling, Ralph, Spix, Claudia, Stefanowicz, Joanna, Strauss, Gabriele, Uitterlinden, Andre G., van den Berg, Marleen, van der Kooi, Anne-Lotte, van Dijk, Marloes, van Leeuwen, Flora, Zolk, Oliver, Zoeller, Daniela, Kaatsch, Peter, Byrne, Julianne, Grabow, Desiree, Campbell, Helen, O'Brien, Kylie, Bielack, Stefan, Zehnhoff-Dinnesen, Antoinette Am, Calaminus, Gabriele, Kremer, Leontien, Langer, Thorsten, van den Heuvel-Eibrink, Marry M., van Dulmen-den Broeder, Eline, Baust, Katja, Bautz, Andrea, Beck, Jörn D., Berger, Claire, Binder, Harald, Borgmann-Staudt, Anja, Broer, Linda, Cario, Holger, Casagranda, Leonie, Clemens, Eva, Deuster, Dirk, de Vries, Andrica, Dirksen, Uta, Winther, Jeanette Falck, Fossa, Sophie, Font-Gonzalez, Anna, Grandage, Victoria, Haupt, Riccardo, Hecker-Nolting, Stefanie, Hjorth, Lars, Kaiser, Melanie, Kenborg, Line, Kepak, Tomas, Kepakova, Katerina, Knudsen, Lisbeth E., Krawczuk-Rybak, Maryna, Kruseova, Jarmila, Kuehni, Claudia E., Kunstreich, Marina, Kuonen, Rahel, Lackner, Herwig, Leiper, Alison, Loeffen, Erik A. H., Luks, Ales, Modan-Moses, Dalit, Mulder, Renee, Parfitt, Ross, Paul, Norbert W., Ranft, Andreas, Ruud, Ellen, Schilling, Ralph, Spix, Claudia, Stefanowicz, Joanna, Strauss, Gabriele, Uitterlinden, Andre G., van den Berg, Marleen, van der Kooi, Anne-Lotte, van Dijk, Marloes, van Leeuwen, Flora, Zolk, Oliver, Zoeller, Daniela, and Kaatsch, Peter

Published
2018

166. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Author

Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, Hjorth, Lars, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, and Hjorth, Lars

Abstract

Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).

Published
2018

167. Symptom interval and treatment burden for patients with malignant central nervous system germ cell tumours.

Author

Hayden, James, Murray, Matthew J., Bartels, Ute, Ajithkumar, Thankamma, Muthusamy, Brinda, Penn, Anthony, Calaminus, Gabriele, and Nicholson, James

Subjects
CENTRAL nervous system, GERM cells, CENTRAL nervous system tumors, GERM cell tumors, DIABETES insipidus, CANCER, INTRACRANIAL pressure, BRAIN tumor treatment, BRAIN tumor diagnosis, RESEARCH, RESEARCH methodology, MEDICAL care, PATIENTS, RETROSPECTIVE studies, EARLY detection of cancer, EVALUATION research, MEDICAL cooperation, TREATMENT effectiveness, BRAIN tumors, COMPARATIVE studies, ECONOMIC aspects of diseases
Abstract

Objective: Patients with central nervous system germ cell tumours (CNS-GCTs) commonly initially present to primary care or general paediatricians. Prolonged symptom intervals (SI) are frequently seen in CNS-GCTs and have been associated with inferior outcomes in other brain tumours. This study reviewed the clinical presentation of CNS-GCTs and examined the effect of prolonged SI.Design/setting/patients/outcomes: International multicentre 10-year retrospective study (2002-2011 inclusive), across six international paediatric oncology treatment centres. All newly diagnosed patients with CNS-GCT were included. Main outcome measure was time interval from first symptom to diagnosis.Results: The study cohort included 86 (58 males:28 female) patients (59 'germinoma' and 27 'non-germinomatous' GCTs), with tumours being pineal (n=33), suprasellar (n=25), bifocal (pineal+suprasellar; n=24) and 'other' site (n=4), of which 16 (19%) were metastatic. Median age at diagnosis was 14 years (0-23 years). The time to diagnosis from first symptom (SI) was 0-69 months (median 3 months, mean 9 months). A prolonged SI (>6 months) was observed in 28/86 patients (33%) and significantly associated with metastatic disease (11/28 (39%) vs 5/58 (9%); p=0.002)) at diagnosis, but not overall survival. With prolonged SI, endocrine symptoms, particularly diabetes insipidus, were more common (21/28 (75%) vs 14/58 (24%) patients; p<0.002), but raised intracranial pressure (RICP) was less frequent (4/28 (14%) vs 43/58 (74%) patients; p<0.001)) at first symptom.Conclusions: One-third of patients with CNS-GCT have >6 months of symptoms prior to diagnosis. Delayed diagnosis is associated with metastatic disease. Early symptom recognition, particularly related to visual and hormonal disturbances in the absence of RICP, may improve timely diagnosis, reduce metastatic disease frequency and consequently reduce treatment burden and late effects. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

169. GERM-12. PITUITARY FAILURES IN CNS MIXED MALIGNANT GERM CELL TUMORS (MMGCTs). EXPERIENCE GENERATED IN SIOP CNS GCT 96

Author

Kuhrt, Christian Asmus, primary, Kortmann, Rolf Dieter, additional, Frappaz, Didier, additional, Saran, Frank, additional, Garre, Maria Luisa, additional, Müller, Jans-Enno, additional, Ricardi, Umberto, additional, Czech, Thomas, additional, Alapetite, Claire, additional, Nicholson, James C, additional, and Calaminus, Gabriele, additional

Published
2018
Full Text
View/download PDF

170. QOL-36. QUALITY OF SURVIVAL IN SIOPE BRAIN TUMOUR CLINICAL TRIALS FOR CHILDREN AGED LESS THAN 5 YEARS: DEVELOPMENT OF A CLINICAL TRIAL PROTOCOL

Author

Limond, Jenny, primary, Thomas, Sophie, additional, Bull, Kim, additional, Lemiere, Jurgen, additional, Traunwieser, Thomas, additional, Spoudeas, Helen, additional, Van Santen, Hanneke M, additional, Weiler-Wichtl, Liesa, additional, Lüttich, Peggy, additional, Calaminus, Gabriele, additional, and Chevignard, Mathilde, additional

Published
2018
Full Text
View/download PDF

175. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology

Author

Ripperger, Tim, Bielack, Stefan S., Borkhardt, Arndt, Brecht, Ines B., Burkhardt, Birgit, Calaminus, Gabriele, Debatin, Klaus-Michael, Deubzer, Hedwig, Dirksen, Uta, Eckert, Cornelia, Eggert, Angelika, Erlacher, Miriam, Fleischhack, Gudrun, Fruehwald, Michael C., Gnekow, Astrid, Goehring, Gudrun, Graf, Norbert, Hanenberg, Helmut, Hauer, Julia, Hero, Barbara, Hettmer, Simone, von Hoff, Katja, Horstmann, Martin, Hoyer, Juliane, Illig, Thomas, Kaatsch, Peter, Kappler, Roland, Kerl, Kornelius, Klingebiel, Thomas, Kontny, Udo, Kordes, Uwe, Koerholz, Dieter, Koscielniak, Ewa, Kramm, Christof M., Kuhlen, Michaela, Kulozik, Andreas E., Lamottke, Britta, Leuschner, Ivo, Lohmann, Dietmar R., Meinhardt, Andrea, Metzler, Markus, Meyer, Lder H., Moser, Olga, Nathrath, Michaela, Niemeyer, Charlotte M., Nustede, Rainer, Pajtler, Kristian W., Paret, Claudia, Rasche, Mareike, Reinhardt, Dirk, Riess, Olaf, Russo, Alexandra, Rutkowski, Stefan, Schlegelberger, Brigitte, Schneider, Dominik, Schneppenheim, Reinhard, Schrappe, Martin, Schroeder, Christopher, von Schweinitz, Dietrich, Simon, Thorsten, Sparber-Sauer, Monika, Spix, Claudia, Stanulla, Martin, Steinemann, Doris, Strahm, Brigitte, Temming, Petra, Thomay, Kathrin, von Bueren, Andre O., Vorwerk, Peter, Witt, Olaf, Wlodarski, Marcin, Woessmann, Willy, Zenker, Martin, Zimmermann, Stefanie, Pfister, Stefan M., Kratz, Christian P., Ripperger, Tim, Bielack, Stefan S., Borkhardt, Arndt, Brecht, Ines B., Burkhardt, Birgit, Calaminus, Gabriele, Debatin, Klaus-Michael, Deubzer, Hedwig, Dirksen, Uta, Eckert, Cornelia, Eggert, Angelika, Erlacher, Miriam, Fleischhack, Gudrun, Fruehwald, Michael C., Gnekow, Astrid, Goehring, Gudrun, Graf, Norbert, Hanenberg, Helmut, Hauer, Julia, Hero, Barbara, Hettmer, Simone, von Hoff, Katja, Horstmann, Martin, Hoyer, Juliane, Illig, Thomas, Kaatsch, Peter, Kappler, Roland, Kerl, Kornelius, Klingebiel, Thomas, Kontny, Udo, Kordes, Uwe, Koerholz, Dieter, Koscielniak, Ewa, Kramm, Christof M., Kuhlen, Michaela, Kulozik, Andreas E., Lamottke, Britta, Leuschner, Ivo, Lohmann, Dietmar R., Meinhardt, Andrea, Metzler, Markus, Meyer, Lder H., Moser, Olga, Nathrath, Michaela, Niemeyer, Charlotte M., Nustede, Rainer, Pajtler, Kristian W., Paret, Claudia, Rasche, Mareike, Reinhardt, Dirk, Riess, Olaf, Russo, Alexandra, Rutkowski, Stefan, Schlegelberger, Brigitte, Schneider, Dominik, Schneppenheim, Reinhard, Schrappe, Martin, Schroeder, Christopher, von Schweinitz, Dietrich, Simon, Thorsten, Sparber-Sauer, Monika, Spix, Claudia, Stanulla, Martin, Steinemann, Doris, Strahm, Brigitte, Temming, Petra, Thomay, Kathrin, von Bueren, Andre O., Vorwerk, Peter, Witt, Olaf, Wlodarski, Marcin, Woessmann, Willy, Zenker, Martin, Zimmermann, Stefanie, Pfister, Stefan M., and Kratz, Christian P.

Abstract

Heritable predisposition is an important cause of cancer in children and adolescents. Although a large number of cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more pediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. In a consensus meeting in the beginning of 2016, we convened experts in Human Genetics and Pediatric Hematology/Oncology to review the available data, to categorize the large amount of information, and to develop recommendations regarding when a cancer predisposition syndrome should be suspected in a young oncology patient. This review summarizes the current knowledge of cancer predisposition syndromes in pediatric oncology and provides essential information on clinical situations in which a childhood cancer predisposition syndrome should be suspected.

Published
2017

176. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOSan open-label, international, randomised controlled trial-1): an open-label, international, randomised controlled trial

Author

Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, and Whelan, Jeremy S

Abstract

BACKGROUND:We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma.METHODS:EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m2, doxorubicin 37·5 mg/m2 per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m2 over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m2) at 2·8 g/m2 per day with equidose mesna uroprotection, followed by etoposide 100 mg/m2 per day over 1 h on days 1-5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030.FINDINGS:Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78-1·23]); hazards were non-proportional (p=0·0003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically doxorubicin and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically doxorubicin). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrexate.INTERPRETATION:EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival. The results define standard of care for this population. New strategies are required to improve outcomes in this setting.FUNDING:UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.

Published
2016

177. Questionnaire-based reports of Quality of Survival and direct assessments of cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial

Author

Câmara-Costa, Hugo, Calaminus, Gabriele, Resch, Anika, Kieffer, Virginie, Lalande, Clémence, Poggi, Geraldina, Kennedy, Colin, Bull, Kim, Weiner, Andreas, von Hoff, Katja, Grill, Jacques, Doz, François, Rutkowski, Stefan, Massimino, Maura, Kortmann, Rolf-Dieter, Lannering, Birgitta, Dellatolas, Georges, and Chevignard, Mathilde

Abstract

Background: the relationship between direct assessments of cognitive performance and questionnaires assessing quality of survival (QoS) is reported to be weak-to-nonexistent. Conversely, the associations between questionnaires evaluating distinct domains of QoS tend to be strong. This pattern remains understudied.Methods: in the HIT-SIOP PNET4 randomized controlled trial, cognitive assessments, including Full Scale, Verbal and Performance IQ, Working Memory, and Processing Speed, were undertaken in 137 survivors of standard risk medulloblastoma from four European countries. QoS questionnaires, including self and/or parent reports of the Behavior Rating Inventory of Executive Function, the Health Utilities Index, the Strengths and Difficulties Questionnaire, and the Pediatric Quality of Life Inventory, were completed in 151survivors.Correlations of direct cognitive assessments, QoS questionnaires, and clinical data were examined in participants with both assessments available (n=86).Results: correlations between direct measures of cognitive performance and QoS questionnaires were weak, except for moderate correlations between the BRIEF Metacognition index (parent-report) and working memory (r=.32) and between health status (self-report) and cognitive outcomes (.35-.44). Correlations among QoS questionnaires were moderate to strong both for parent and self-report (.39-.76). Principal Component Analysis demonstrated that questionnaires and cognitive assessments loaded on two separate factors.Conclusions: we hypothesize that the strong correlations among QoS questionnaires is partially attributable to the positive/negative polarity of all questions of the questionnaires, coupled with the relative absence of disease-specific questions. These factors may be influenced by respondents’ personality and emotional characteristics, unlike direct assessments of cognitive functioning, and should be taken into account in clinical trials.

Published
2016

178. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines

Author

Schönberger, Stefan, primary, van Beekum, Cornelius, additional, Götz, Barbara, additional, Nettersheim, Daniel, additional, Schorle, Hubert, additional, Schneider, Dominik T., additional, Casati, Anna, additional, Craveiro, Rogerio B., additional, Calaminus, Gabriele, additional, and Dilloo, Dagmar, additional

Published
2017
Full Text
View/download PDF

179. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial

Author

Calaminus, Gabriele, primary, Frappaz, Didier, additional, Kortmann, Rolf Dieter, additional, Krefeld, Barbara, additional, Saran, Frank, additional, Pietsch, Torsten, additional, Vasiljevic, Alexandre, additional, Garre, Maria Luisa, additional, Ricardi, Umberto, additional, Mann, Jillian R, additional, Göbel, Ulrich, additional, Alapetite, Claire, additional, Murray, Matthew J, additional, and Nicholson, James C, additional

Published
2017
Full Text
View/download PDF

181. Clinical and Radiologic Outcomes in Adults and Children Treated with Pencil-Beam Scanning Proton Therapy for Low-Grade Glioma

Author

Badiyan, Shahed N., primary, Ulmer, Stephan, additional, Ahlhelm, Frank J., additional, Fredh, Anna S. M., additional, Kliebsch, Ulrike, additional, Calaminus, Gabriele, additional, Bolsi, Alessandra, additional, Albertini, Francesca, additional, Leiser, Dominic, additional, Timmermann, Beate, additional, Malyapa, Robert S., additional, Schneider, Ralf, additional, Lomax, Antony J., additional, and Weber, Damien C., additional

Published
2017
Full Text
View/download PDF

182. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology

Author

Ripperger, Tim, primary, Bielack, Stefan S., additional, Borkhardt, Arndt, additional, Brecht, Ines B., additional, Burkhardt, Birgit, additional, Calaminus, Gabriele, additional, Debatin, Klaus-Michael, additional, Deubzer, Hedwig, additional, Dirksen, Uta, additional, Eckert, Cornelia, additional, Eggert, Angelika, additional, Erlacher, Miriam, additional, Fleischhack, Gudrun, additional, Frühwald, Michael C., additional, Gnekow, Astrid, additional, Goehring, Gudrun, additional, Graf, Norbert, additional, Hanenberg, Helmut, additional, Hauer, Julia, additional, Hero, Barbara, additional, Hettmer, Simone, additional, von Hoff, Katja, additional, Horstmann, Martin, additional, Hoyer, Juliane, additional, Illig, Thomas, additional, Kaatsch, Peter, additional, Kappler, Roland, additional, Kerl, Kornelius, additional, Klingebiel, Thomas, additional, Kontny, Udo, additional, Kordes, Uwe, additional, Körholz, Dieter, additional, Koscielniak, Ewa, additional, Kramm, Christof M., additional, Kuhlen, Michaela, additional, Kulozik, Andreas E., additional, Lamottke, Britta, additional, Leuschner, Ivo, additional, Lohmann, Dietmar R., additional, Meinhardt, Andrea, additional, Metzler, Markus, additional, Meyer, Lüder H., additional, Moser, Olga, additional, Nathrath, Michaela, additional, Niemeyer, Charlotte M., additional, Nustede, Rainer, additional, Pajtler, Kristian W., additional, Paret, Claudia, additional, Rasche, Mareike, additional, Reinhardt, Dirk, additional, Rieß, Olaf, additional, Russo, Alexandra, additional, Rutkowski, Stefan, additional, Schlegelberger, Brigitte, additional, Schneider, Dominik, additional, Schneppenheim, Reinhard, additional, Schrappe, Martin, additional, Schroeder, Christopher, additional, von Schweinitz, Dietrich, additional, Simon, Thorsten, additional, Sparber-Sauer, Monika, additional, Spix, Claudia, additional, Stanulla, Martin, additional, Steinemann, Doris, additional, Strahm, Brigitte, additional, Temming, Petra, additional, Thomay, Kathrin, additional, von Bueren, Andre O., additional, Vorwerk, Peter, additional, Witt, Olaf, additional, Wlodarski, Marcin, additional, Wössmann, Willy, additional, Zenker, Martin, additional, Zimmermann, Stefanie, additional, Pfister, Stefan M., additional, and Kratz, Christian P., additional

Published
2017
Full Text
View/download PDF

184. Development of curative therapies for ewing sarcomas by interdisciplinary cooperative groups in Europe : Entwicklung kurativer Therapien für Ewing-Sarkome durch interdisziplinäre Kooperationen in Europa

Author

Bölling, Tobias, Braun-Munzinger, Gabriele, Burdach, Stefan E. G., Calaminus, Gabriele, Craft, Alan W. C., Delattre, Oliver O., Deley, Marie Cécile Le, Dirksen, Uta, Dockhorn-Dworniczak, B., Dunst, Jürgen, Engel, Sean C., Faldum, Andreas, Fröhlich, Birgit, Gadner, Helmut, Göbel, Ulrich B., Gosheger, Georg, Hardes, Jendrik, Hawkins, Douglas S., Hjort, Lars, Hoffmann, Christiane, Kovar, Heinrich, Kruseová, Jarmila, Ladenstein, Ruth Lydia, Leuschner, Ivo, Lewis, Ian J., Oberlin, Odile, Paulussen, Michael, Potratz, Jenny C., Ranft, Andreas, Rössig, Claudia, Rübe, Christian, Sauer, Rolf, Schober, Otmar, Schuck, Andreas, Timmermann, Beate, Tirode, Franck, Van Den Berg, Henk Pieter, Van Valen, Frans, Vieth, Volker V. V., Willich, Normann A., Winkelmann, Wilfried, Whelan, Jeremy S., and Womer, Richard B.

Subjects
Medizin
Published
2015

185. The Postopera tive Quality of Life in Children and Adolescents with Craniopharyngioma: Results of a Prospective Multicenter Study.

Author

Eveslage, Maria, Calaminus, Gabriele, Warmuth-Metz, Monika, Kortmann, Rolf-Dieter, Pohl, Fabian, Timmermann, Beate, Schuhmann, Martin Ulrich, Flitsch, Jörg, Faldum, Andreas, and Müller, Hermann Lothar

Abstract

Background: Craniopharyngioma is a tumor of low histological malignancy resulting from an anomaly of embryonic development. Affected children and adolescents are being studied with respect to their quality of life, progression-free survival, and overall survival in the framework of the ongoing KRANIOPHARYNGEOM 2007 project. Methods: This prospective, multicenter project consists of a randomized trial with an adaptive design combined with a purely observational study. The randomized, unblinded trial includes patients whose tumors have been incompletely resected and is intended to compare the outcomes of immediate postoperative radiotherapy versus radiotherapy on progression. Its primary endpoint is quality of life as assessed subjectively by the patients themselves with the "Pediatric Quality of Life" questionnaire (PEDQOL). In exploratory analyses, linear mixed models were used to study the effect of further factors on quality of life. Results: An interim intention-to-treat analysis of the randomized trial revealed only minor differences between the treatment arms with respect to quality of life (n = 24). The exploratory analyses (n = 131) showed that preoperative involvement of, or operative damage to, the anterior and posterior regions of the hypothalamus was associated with a lower quality of life. Complete resection was followed by a lower quality of life than incomplete resection. Radiotherapy, a common treatment for tumors that progress after incomplete resection, was also associated with a lower quality of life. Conclusion: Hypothalamus-sparing treatment approaches are recommended to optimize the quality of life of children and adolescents with craniopharyngioma. The available evidence does not support any recommendation as to when radiotherapy should be performed after incomplete resection so that the best quality of life can be achieved. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

186. Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Author

Sturm, Dominik, Capper, David, Andreiuolo, Felipe, Gessi, Marco, Kölsche, Christian, Reinhardt, Annekathrin, Sievers, Philipp, Wefers, Annika K., Ebrahimi, Azadeh, Suwala, Abigail K., Gielen, Gerrit H., Sill, Martin, Schrimpf, Daniel, Stichel, Damian, Hovestadt, Volker, Daenekas, Bjarne, Rode, Agata, Hamelmann, Stefan, Previti, Christopher, Jäger, Natalie, Buchhalter, Ivo, Blattner-Johnson, Mirjam, Jones, Barbara C., Warmuth-Metz, Monika, Bison, Brigitte, Grund, Kerstin, Sutter, Christian, Hirsch, Steffen, Dikow, Nicola, Hasselblatt, Martin, Schüller, Ulrich, Koch, Arend, Gerber, Nicolas U., White, Christine L., Buntine, Molly K., Kinross, Kathryn, Algar, Elizabeth M., Hansford, Jordan R., Gottardo, Nicholas G., Schuhmann, Martin U., Thomale, Ulrich W., Hernáiz Driever, Pablo, Gnekow, Astrid, Witt, Olaf, Müller, Hermann L., Calaminus, Gabriele, Fleischhack, Gudrun, Kordes, Uwe, Mynarek, Martin, Rutkowski, Stefan, Frühwald, Michael C., Kramm, Christof M., von Deimling, Andreas, Pietsch, Torsten, Sahm, Felix, Pfister, Stefan M., and Jones, David. T. W.

Published
2024
Full Text
View/download PDF

187. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, Whelan, Jeremy S, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, and Whelan, Jeremy S

Abstract

BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m2, doxorubicin 37·5 mg/m2 per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m2 over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m2) at 2·8 g/m2 per day with equidose mesna uroprotection, followed by etoposide 100 mg/m2 per day over 1 h on days 1-5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030. FINDINGS: Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event

Published
2016

188. ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer.

Author

Nout, Remi, Calaminus, Gabriele, Planchamp, François, Chargari, Cyrus, Lax, Sigurd F., Martelli, Hélène, McCluggage, W Glenn, Morice, Philippe, Pakiz, Maja, Schmid, Maximilian Paul, Stunt, Jonáh, Timmermann, Beate, Vokuhl, Christian, Orbach, Daniel, and Fotopoulou, Christina

Subjects
*VAGINAL cancer, *CANCER patients, *CHILD patients, *GENITALIA, *CANCER patient care
Abstract

• Primary vaginal malignancies are rare, comprising only 2% of all female genital tract malignancies in adults and 4.5% in children. • ESTRO/ESGO/SIOPe societies jointly developed evidence-based guidelines to improve the quality of care for women with vaginal cancer within a multidisciplinary setting. • A nominated international expert panel of 13 clinical practioners formulated evidence based statements, which were reviewed by 112 independent international practitionners. • These guidelines cover comprehensively the diagnostic pathways, surgical, radiotherapeutical and systemic management and follow-up of adult patients and pediatric patients with vaginal tumours. Primary vaginal malignancies are rare, comprising only 2% of all female genital tract malignancies in adults and 4.5% in children. As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynaecological Oncology (ESGO) jointly with the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Pediatric Oncology (SIOPe) developed evidence-based guidelines in order to improve the management of patients with vaginal cancer within a multidisciplinary setting. ESTRO/ESGO/SIOPe nominated practicing clinicians who are involved in the management of vaginal cancer patients and have demonstrated leadership through their expertise in clinical care and research, their national and international engagement and profile as well as dedication to the topics addressed to serve on the expert panel (13 experts across Europe comprising the international development group). To ensure that the statements were evidence based, the current literature was reviewed and critically appraised. In the case of absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Prior to publication, the guidelines were reviewed by 112 independent international practitionners in cancer care delivery and patient representatives and their comments and input were incorporated and addressed accordingly. These guidelines cover comprehensively the diagnostic pathways as well as the surgical, radiotherapeutical and systemic management and follow-up of adult patients (including those with rare histological subtypes) and pediatric patients (vaginal rhabdomyosarcoma and germ cell tumours) with vaginal tumours. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

189. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Author

Marina, Neyssa M, primary, Smeland, Sigbjørn, additional, Bielack, Stefan S, additional, Bernstein, Mark, additional, Jovic, Gordana, additional, Krailo, Mark D, additional, Hook, Jane M, additional, Arndt, Carola, additional, van den Berg, Henk, additional, Brennan, Bernadette, additional, Brichard, Bénédicte, additional, Brown, Ken L B, additional, Butterfass-Bahloul, Trude, additional, Calaminus, Gabriele, additional, Daldrup-Link, Heike E, additional, Eriksson, Mikael, additional, Gebhardt, Mark C, additional, Gelderblom, Hans, additional, Gerss, Joachim, additional, Goldsby, Robert, additional, Goorin, Allen, additional, Gorlick, Richard, additional, Grier, Holcombe E, additional, Hale, Juliet P, additional, Hall, Kirsten Sundby, additional, Hardes, Jendrik, additional, Hawkins, Douglas S, additional, Helmke, Knut, additional, Hogendoorn, Pancras C W, additional, Isakoff, Michael S, additional, Janeway, Katherine A, additional, Jürgens, Heribert, additional, Kager, Leo, additional, Kühne, Thomas, additional, Lau, Ching C, additional, Leavey, Patrick J, additional, Lessnick, Stephen L, additional, Mascarenhas, Leo, additional, Meyers, Paul A, additional, Mottl, Hubert, additional, Nathrath, Michaela, additional, Papai, Zsuzsanna, additional, Randall, R Lor, additional, Reichardt, Peter, additional, Renard, Marleen, additional, Safwat, Akmal Ahmed, additional, Schwartz, Cindy L, additional, Stevens, Michael C G, additional, Strauss, Sandra J, additional, Teot, Lisa, additional, Werner, Mathias, additional, Sydes, Matthew R, additional, and Whelan, Jeremy S, additional

Published
2016
Full Text
View/download PDF

191. Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy

Author

Leiser, Dominic, primary, Calaminus, Gabriele, additional, Malyapa, Robert, additional, Bojaxhiu, Beat, additional, Albertini, Francesca, additional, Kliebsch, Ulrike, additional, Mikroutsikos, Lorentzos, additional, Morach, Petra, additional, Bolsi, Alessandra, additional, Walser, Marc, additional, Timmermann, Beate, additional, Lomax, Tony, additional, Schneider, Ralf, additional, and Weber, Damien C., additional

Published
2016
Full Text
View/download PDF

193. QOS-17QUESTIONNAIRE-BASED REPORTS OF QUALITY OF SURVIVAL (QOS) AND DIRECT ASSESSMENTS OF COGNITIVE PERFORMANCE IN CHILDREN TREATED FOR MEDULLOBLASTOMA IN THE PNET 4 RANDOMIZED CONTROLLED TRIAL

Author

Câmara-Costa, Hugo, primary, Calaminus, Gabriele, additional, Resch, Anika, additional, Kieffer, Virginie, additional, Lalande, Clémence, additional, Poggi, Geraldina, additional, Kennedy, Colin, additional, Bull, Kim, additional, Wiener, Andreas, additional, von Hoff, Katja, additional, Grill, Jacques, additional, Doz, François, additional, Rutkowski, Stefan, additional, Massimino, Maura, additional, Kortmann, Rolf-Dieter, additional, Lannering, Birgitta, additional, Dellatolas, Georges, additional, and Chevignard, Mathilde, additional

Published
2016
Full Text
View/download PDF

195. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Author

Bielack, Stefan S, Smeland, Sigbjørn, Whelan, Jeremy S, Marina, Neyssa, Jovic, Gordana, Hook, Jane M, Krailo, Mark D, Gebhardt, Mark, Pápai, Zsuzsanna, Meyer, James, Nadel, Helen, Randall, R Lor, Deffenbaugh, Claudia, Nagarajan, Rajaram, Brennan, Bernadette, Letson, G Douglas, Teot, Lisa A, Goorin, Allen, Baumhoer, Daniel, Kager, Leo, Werner, Mathias, Lau, Ching C, Sundby Hall, Kirsten, Gelderblom, Hans, Meyers, Paul, Gorlick, Richard, Windhager, Reinhard, Helmke, Knut, Eriksson, Mikael, Hoogerbrugge, Peter M, Schomberg, Paula, Tunn, Per-Ulf, Kühne, Thomas, Jürgens, Heribert, van den Berg, Henk, Böhling, Tom, Picton, Susan, Renard, Marleen, Reichardt, Peter, Gerss, Joachim, Butterfass-Bahloul, Trude, Morris, Carol, Hogendoorn, Pancras C W, Seddon, Beatrice, Calaminus, Gabriele, Michelagnoli, Maria, Dhooge, Catharina, Sydes, Matthew R, Bernstein, Mark, Bielack, Stefan S, Smeland, Sigbjørn, Whelan, Jeremy S, Marina, Neyssa, Jovic, Gordana, Hook, Jane M, Krailo, Mark D, Gebhardt, Mark, Pápai, Zsuzsanna, Meyer, James, Nadel, Helen, Randall, R Lor, Deffenbaugh, Claudia, Nagarajan, Rajaram, Brennan, Bernadette, Letson, G Douglas, Teot, Lisa A, Goorin, Allen, Baumhoer, Daniel, Kager, Leo, Werner, Mathias, Lau, Ching C, Sundby Hall, Kirsten, Gelderblom, Hans, Meyers, Paul, Gorlick, Richard, Windhager, Reinhard, Helmke, Knut, Eriksson, Mikael, Hoogerbrugge, Peter M, Schomberg, Paula, Tunn, Per-Ulf, Kühne, Thomas, Jürgens, Heribert, van den Berg, Henk, Böhling, Tom, Picton, Susan, Renard, Marleen, Reichardt, Peter, Gerss, Joachim, Butterfass-Bahloul, Trude, Morris, Carol, Hogendoorn, Pancras C W, Seddon, Beatrice, Calaminus, Gabriele, Michelagnoli, Maria, Dhooge, Catharina, Sydes, Matthew R, and Bernstein, Mark

Abstract

Purpose EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients and Methods At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). Results Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. Conclusion At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term

Published
2015

196. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy

Author

Weber, Damien C, Ares, Carmen, Malyapa, Robert, Albertini, Francesca, Calaminus, Gabriele, Kliebsch, Ulrike, Mikroutsikos, Lorentzos, Morach, Petra, Bolsi, Alessandra, Lomax, Tony, Schneider, Ralf, Weber, Damien C, Ares, Carmen, Malyapa, Robert, Albertini, Francesca, Calaminus, Gabriele, Kliebsch, Ulrike, Mikroutsikos, Lorentzos, Morach, Petra, Bolsi, Alessandra, Lomax, Tony, and Schneider, Ralf

Abstract

The aim of this analysis was to assess the early clinical results of pencil beam scanning proton therapy (PT) in the treatment of young children with non-metastatic atypical teratoid/rhabdoid tumor (ATRT) of the CNS. Fifteen children (male, n = 8, 53 %) were treated with PT between May 2008 and January 2013. Mean age at diagnosis was 17.4 ± 7.0 months. The localization was infratentorial in 9 (60 %) patients. Gross total resection of the primary tumors was achieved in 7 (47 %) patients. The dose administered focally under sedation was 54 Gy (RBE). After a median follow-up of 33.4 months (range 9.7-69.2), 3 (20 %), 4 (27 %) and 2 (13 %) patients presented with local failure (LF), distant brain failure (DBF) and spinal failure (SF), respectively. Six patients died, all of tumor progression. The 2-year overall- and progression-free survival was 64.6 and 66.0 %. Tumor location (supratentorial) and the extent of surgical resection (non-gross total resection) were negative prognostic factors for both OS and PFS. PT was well tolerated. No grade >2 acute toxicity was observed. The estimated 2-year toxicity-free survival was 90 %. As assessed by the PedsQoL proxy, no decrease in QoL was observed after PT. We conclude that PBS PT is an effective treatment for young children with ATRT. After PT, with or without concomitant chemotherapy, two third of the patients survived >2 years. Acute toxicity was manageable. Longer follow-up and larger numbers of patients are needed to assess long-term outcomes and treatment-induced toxicity.

Published
2015

198. Evaluation of an anthroposophic supportive treatment intervention (ASTI) in children with malignant diseases during intensive chemotherapy

Author

Seifert, Georg, primary, Henze, Günter, additional, Calaminus, Gabriele, additional, Hoff-Heise, Claudia vom, additional, Schlodder, Dietrich, additional, Rieger, Sabine, additional, Felenda, Jennifer, additional, Beckmann, Christiane, additional, Hufnagel, Rebecca, additional, Semaca, Cristina, additional, and Längler, Alfred, additional

Published
2015
Full Text
View/download PDF

199. Strategies to improve the quality of survival for childhood brain tumour survivors

Author

Tallen, Gesche, primary, Resch, Anika, additional, Calaminus, Gabriele, additional, Wiener, Andreas, additional, Leiss, Ulrike, additional, Pletschko, Thomas, additional, Friedrich, Carsten, additional, Langer, Thorsten, additional, Grabow, Desiree, additional, Driever, Pablo Hernáiz, additional, Kortmann, Rolf-Dieter, additional, Timmermann, Beate, additional, Pietsch, Torsten, additional, Warmuth-Metz, Monika, additional, Bison, Brigitte, additional, Thomale, Ulrich-Wilhelm, additional, Krauss, Jürgen, additional, Mynarek, Martin, additional, von Hoff, Katja, additional, Ottensmeier, Holger, additional, Frühwald, Michael, additional, Kramm, Christof M., additional, Temming, Petra, additional, Müller, Hermann L., additional, Witt, Olaf, additional, Kordes, Uwe, additional, Fleischhack, Gudrun, additional, Gnekow, Astrid, additional, and Rutkowski, Stefan, additional

Published
2015
Full Text
View/download PDF

200. Quality of Life (QoL) in children and adolescents with paediatric malignancies under anthroposophic supportive treatment

Author

Calaminus, Gabriele, primary, Längler, Alfred, additional, Henze, Günter, additional, vom Hoff-Heise, Claudia, additional, Schlodder, Dietrich, additional, Rieger, Sabine, additional, Felenda, Jennifer, additional, Beckmann, Christiane, additional, Hufnagel, Rebecca, additional, Semaca, Cristina, additional, and Seifert, Georg, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results